Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma

European Journal of Ophthalmology

Volumn 11, Issue SUPPL. 2, 2001, Pages

  Wheeler, L A ^a   Woldemussie, E ^a  

^a ALLERGAN INC   (United States)

Author keywords

Alpha 2 adrenoreceptor agonist; Brimonidine; Glaucoma; Neuroprotection; Neuroprotective signalling pathways

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; TIMOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL LOSS; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SPECIFICITY; GLAUCOMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; ISCHEMIC OPTIC NEUROPATHY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; RAT; RETINA; RETINA GANGLION CELL; SIGNAL TRANSDUCTION;

EID: 0034766798     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210101102s03     Document Type: Conference Paper

References (31)

1. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport
2. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage
3. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis
4. Retinal ganglion cell death in glaucoma: The how, the why and the maybe
5. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes
6. Optic nerve degeneration and potential neuroprotection: Implications for glaucoma
7. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha-2-adrenergic antagonist atipamezole
8. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia
9. Time course of pre or post treatment by brimonidine on neuroprotection in rat optic nerve injury model
10. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration
11. Neuroprotection effect of brimonidine on adult rat retinal ganglion cells after increased intraocular pressure
12. Neuroprotective effect of brimonidine in chronic ocular hypertensive rats
13. From the lab to the clinic: Activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury
14. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis by inducing new protein synthesis that maintains mitochondrial pore closure
15. Fast axonal diffusion of 3000 molecular weight dextran amines
16. Therapeutic use of α2-adrenceptor agonists in glaucoma
17. Changing therapeutic paradigms in glaucoma management
18. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates
19. Neuroprotective effect of ocular hypotensive agent brimonidine
20. Use of pharmacological agents to modulate neuronal cell death and injury
21. The scotopic electroretinogram of macaque after retinal ganglion cell loss from experimental glaucoma
22. Comparison of ganglion cell loss and cone loss in experimental glaucoma
23. Brimonidine concentrations in the posterior segment of patients during Alphagan® treatment
24. Alpha-2 adrenoceptor agonists preserve retinal function-following transient ischemia by inhibiting vitreal glutamate and aspartate accumulation
25. Functional protection of rat retina from ischemic injury by brimonidine
26. Short and long-term neuroprotection of a selective alpha-2 agonist (AGN 191103) on retinal ganglion cell survival after ischaemia induced by selective ligature of the ophthalmic vessels
27. Retinal ganglion cell death in mice after nerve crush injury: Effects of superoxide dismutase overexpression and protection by brimonidine
28. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage
29. Brimonidine protects photoreceptors and visual function after light damage
30. Brimonidine rescues photoreceptors from degeneration induced by retinal pigment epithelium removal in vitro